Atrium Therapeutics, Inc. RNA
Set alert
As of Nov 2, 10:30 AM ET
- YTD
- -42.51%
- 1 year
- -42.51%
- Open
- 8.22
- Prev close
- 8.27
- Mkt cap
- 145.06M
- Vol
- 83.24K
- Avg vol
- 279.13K
- EPS
- -5.44
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.19
- High
- 8.52
- Forward P/E
- -3.67
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.25%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 15.47
- 200-d avg
- 15.47
- 1y target
- 0.00
News
-
3 hours ago benzinga.com
Atrium Therapeutics To Present New Nonclinical Data On ATR 1072 For Potential Treatment Of PRKAG2 At The American Heart Association Scientific Sessions On November 6; ATR 1072 Impacted Key Characteristics Of PRKAG2, Including Accumulation Of Cardiac Glycogen And Cardiac Hypertrophy
Data further reinforce scientific rationale for ATR 1072 targeting the root cause of PRKAG2 syndromeThe nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2…
-
5 days ago benzinga.com
HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Atrium Therapeutics (NASDAQ:RNA) with a Buy and lowers the price target from $25 to $20.
-
6 days ago benzinga.com
Atrium Therapeutics Doses First Patient In Its Phase 1/2 Corventis Clinical Trial Evaluating ATR 1072 For Potential Treatment Of PRKAG2 Syndrome; Expects Initial Proof-Of-Concept Data In H2 2027
Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that the first…
6 days ago prnewswire.com
Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
-- Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants -- -- Initial proof of concept data expected in second half of 2027 -- SAN DIEGO, Oct. 27, 2026 /PRNewswire/ --…
1 week ago benzinga.com
This Constellation Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Buy ratings for CleanSpark, Constellation Energy and Atrium; Outperform for Kardigan; Neutral for Northwest Natural.
-
1 week ago benzinga.com
Roth Capital Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $15
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $15.
-
1 week ago benzinga.com
Shareholder Yakira Capital Urges Atrium Therapeutics To Explore Strategic Sale Or Partnerships, Citing 44% Stock Decline, $50M Dilutive Financing
Yakira urges Board to explore strategic alternatives before further cash burn and dilution erode shareholder value; questions decision to raise $50 million after shares fell approximately 44% at a…
-
3 weeks ago benzinga.com
Atrium Therapeutics Announces $50M Private Placement Of 5,170,384 Shares And Pre-Funded Warrants To Purchase Up To 1,134,930 Shares At ~$7.93/Unit
Company entered into a securities purchase agreement (the "purchase agreement") with a group of leading institutional investors for a private placement financing (the "private placement"). The private
1 month ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology…
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Atrium Therapeutics, Maintains $25 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Atrium Therapeutics (NASDAQ:RNA) with a Buy and maintains $25 price target.
-
2 months ago benzinga.com
Atrium Therapeutics Q2 EPS $(1.18) Misses $(1.01) Estimate, Sales $3.004M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(1.18) per share which missed the analyst consensus estimate of $(1.01) by 16.83 percent. This is a 2.48 percent increase over losses of…
2 months ago benzinga.com
This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
-
2 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Atrium Therapeutics with Buy Rating, Announces Price Target of $25
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Buy rating and announces Price Target of $25.
-
3 months ago benzinga.com
Atrium Therapeutics Says FDA Clears IND Application Allowing It To Move Forward With Corventis Phase 1/2 Clinical Trial To Evaluate ATR 1072 For Treatment Of PRKAG2 Syndrome
-- ATR 1072 is the company's first precision cardiology program to enter the clinic ---- Corventis™ will be the first clinical trial for people living with PRKAG2 syndrome that evaluates a potential…
-
4 months ago benzinga.com
Cantor Fitzgerald Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.
-
5 months ago benzinga.com
Leerink Partners Initiates Coverage On Atrium Therapeutics with Outperform Rating, Announces Price Target of $25
Leerink Partners analyst Joseph Schwartz initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Outperform rating and announces Price Target of $25.
-
5 months ago benzinga.com
Atrium Therapeutics Q1 EPS $(0.97) Beats $(1.10) Estimate, Sales $19.635M Beat $2.000M Estimate
Atrium Therapeutics (NASDAQ:RNA) reported quarterly losses of $(0.97) per share which beat the analyst consensus estimate of $(1.10) by 11.82 percent. This is a 7.78 percent decrease over losses of…
6 months ago benzinga.com
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month
Oversold stocks in health care sector present buying opportunity. RSI compares stock's strength on up/down days & predicts short-term performance. Top oversold stocks: KNSA (28) NNOX (28.2) RNA…
-
7 months ago benzinga.com
Wells Fargo Initiates Coverage On Atrium Therapeutics with Overweight Rating, Announces Price Target of $25
Wells Fargo analyst Yanan Zhu initiates coverage on Atrium Therapeutics (NASDAQ:RNA) with a Overweight rating and announces Price Target of $25.
8 months ago benzinga.com
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Why Applied Optoelectronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
-
10 months ago benzinga.com
The Year-End 2025 Biotech Rally And What It Means For 2026
The Year-End 2025 Biotech Rally And What It Means For 2026
10 months ago benzinga.com
Top 2 Health Care Stocks That May Keep You Up At Night In December
Top 2 Health Care Stocks That May Keep You Up At Night In December
11 months ago benzinga.com
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.
-
11 months ago benzinga.com
Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today
Here's How Much $100 Invested In Avidity Biosciences 5 Years Ago Would Be Worth Today
-
11 months ago benzinga.com
Looking Into Avidity Biosciences Inc's Recent Short Interest
Looking Into Avidity Biosciences Inc's Recent Short Interest
-
11 months ago benzinga.com
Avidity Biosciences Announces MAP For Investigational Therapy Delpacibart Zotadirsen For Eligible People With Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping In US
Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its…
-
11 months ago benzinga.com
Chardan Capital Maintains Neutral on Avidity Biosciences, Maintains $72 Price Target
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Neutral and maintains $72 price target.
-
11 months ago benzinga.com
Avidity Biosciences Q3 EPS $(1.27) Misses $(1.11) Estimate, Sales $12.475M Beat $1.932M Estimate
Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(1.27) per share which missed the analyst consensus estimate of $(1.11) by 13.9 percent. This is a 95.38 percent decrease over losses of…
-
1 year ago benzinga.com
$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today
$1000 Invested In Avidity Biosciences 5 Years Ago Would Be Worth This Much Today
-
1 year ago benzinga.com
TD Cowen Downgrades Avidity Biosciences to Hold, Lowers Price Target to $74
TD Cowen analyst Ritu Baral downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and lowers the price target from $78 to $74.
1 year ago benzinga.com
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday
1 year ago benzinga.com
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
This Boot Barn Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
-
1 year ago benzinga.com
Chardan Capital Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Chardan Capital analyst Keay Nakae downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $75 to $72.
1 year ago benzinga.com
Novartis Maintains Outlook Even As Generics Bite Into Profits
Novartis Q3 sales rose 8% to $13.91 billion, missing estimates, as Kisqali and Kesimpta drove growth while U.S. generics weighed on results.
-
1 year ago benzinga.com
RBC Capital Downgrades Avidity Biosciences to Sector Perform, Raises Price Target to $72
RBC Capital analyst Luca Issi downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Sector Perform and raises the price target from $61 to $72.
1 year ago benzinga.com
'Merger Monday' Makes Comeback As US M&A Tops $80 Billion In 24 Hours
U.S. companies have struck more than $80 billion worth of deals in the past 24 hours, in the latest sign that mergers and acquisitions (M&A) are picking up after the tariff-induced cool-off earlier…
1 year ago benzinga.com
Avidity Biosciences Soars After $72 Per Share Novartis Takeover
Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
1 year ago benzinga.com
Citigroup Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
Citigroup analyst Geoff Meacham downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $75 to $72.
-
1 year ago benzinga.com
Raymond James Downgrades Avidity Biosciences to Market Perform
Raymond James analyst Martin Auster downgrades Avidity Biosciences (NASDAQ:RNA) from Strong Buy to Market Perform.
1 year ago benzinga.com
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
1 year ago benzinga.com
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
1 year ago benzinga.com
This Harley-Davidson Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
This Harley-Davidson Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
-
1 year ago benzinga.com
Bernstein Downgrades Avidity Biosciences to Market Perform, Raises Price Target to $72
Bernstein analyst William Pickering downgrades Avidity Biosciences (NASDAQ:RNA) from Outperform to Market Perform and raises the price target from $52 to $72.
-
1 year ago benzinga.com
Needham Downgrades Avidity Biosciences to Hold, Maintains Price Target to $65
Needham analyst Joseph Stringer downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Hold and maintains the price target from $65 to $65.
-
1 year ago benzinga.com
HC Wainwright & Co. Downgrades Avidity Biosciences to Neutral, Lowers Price Target to $72
HC Wainwright & Co. analyst Ananda Ghosh downgrades Avidity Biosciences (NASDAQ:RNA) from Buy to Neutral and lowers the price target from $87 to $72.
1 year ago benzinga.com
Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal
Avidity Biosciences (NASDAQ: RNA) shares soar as Novartis (NYSE: NVS) agrees to acquire them for $12 billion in cash.
1 year ago benzinga.com
Stock Market Today: Nasdaq, Dow Jones, S&P 500 Futures Climb Ahead Of Busy Week On Wall Street—Novartis, Nucor, Waste Management In Focus (UPDATED)
Editor’s note: The future prices of benchmark tracking ETFs, and the headline were updated in the story.
1 year ago benzinga.com
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket
Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket